Indications of atypical antipsychotics in the elderly

Expert Review of Clinical Pharmacology

Volumn 8, Issue 1, 2014, Pages 5-7

  McKean, Andrew ^a   Monasterio, Erik ^a  

^a Hillmorton Hospital   (New Zealand)

Author keywords

atypical antipsychotics; clozapine; elderly; indications; off license; olanzapine; quetiapine; risperidone

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR;

AGED; DEMENTIA; DEPRESSION; DIABETES MELLITUS; DRUG INDUSTRY; EFFECT SIZE; EXTRAPYRAMIDAL SYMPTOM; HIP FRACTURE; HUMAN; INSOMNIA; MORTALITY; NURSING HOME; OFF LABEL DRUG USE; POLYPHARMACY; POPULATION; PSYCHOSIS; PUBLICATION; REVIEW; SIDE EFFECT; SUDDEN CARDIAC DEATH; TREATMENT INDICATION; WHISTLEBLOWING; MENTAL DISORDERS;

AGED; ANTIPSYCHOTIC AGENTS; HUMANS; MENTAL DISORDERS; OFF-LABEL USE;

EID: 84916939643     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/17512433.2015.974557     Document Type: Review

References (31)

1. Alexander GC, Gallagher SA, Mascola A, et al. Increasing off-label use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiol Drug Saf 2011;20(2):177-84
2. Monasterio E, McKean A. Off-label use of atypical antipsychotics: a cause for concern? CNS Drugs 2012;26(5):383-90
3. Anon. Top 20 global therapeutic products 2010, Total audited markets. Available from: www.imshealth.com [Last accessed 16 August 2011]
4. Brooks M. Top 100 selling drugs of 2013. Available from: www.medscape.com/ viewarticle/820011 2014. [Last accessed 5 September 2014]
5. Radley DC, Finkelstein MD, Randall S, Stafford S. Off-label prescribing among office-based physicians. Arch Int Med 2006;166:1021-6
6. Monasterio E, McKean A. Off-label use of atypical antipsychotics in Canterbury, New Zealand. New Zealand Med J 2010; 124(1336):24-9
7. Lieberman J, Stroup S, McEvoy J, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23
8. Friedman R. A Call for Caution on Antipsychotic Drugs. New York Times 2012. Available from: www.nytimes.com/ 2012/09/25/health/a-call-for-caution-in-theuse- of-antipsychotic-drugs.html?-r=0 [Last accessed 5 September 2014]
9. Kesselheim A, Mello M and Studdert D. Strategies and practices in off-label marketing of pharmaceuticals: A retrospective analysis of whistleblower complaints. PLoS Med 2011;8:e1000431
10. Kmietowicz Z. Eli Lilly pays record $1.4bn for promoting off-label use of olanzapine. Br Med J 2009;338:b217
11. Hopkins Tanne J. AstraZeneca pays $520m fine for off label marketing BMJ. 2010;340: c2380
12. Kmietowicz Z. Johnson & Johnson to pay $2.2bn to settle charges of false marketing on three drugs. BMJ 2013;347:f6696
13. Maher A, Maglione M, Bagley S, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off label uses in adults. A systematic review and meta-analysis. JAMA 2011;306(12):1359-69
14. Taylor D, Paton C and Kapur S. The Maudsley prescribing guidelines in psychiatry. Published by Wiley-Blackwell; 2012
15. Maglione M, Maher A, Shekelle P, et al. Off label use of atypical antipsychotics: an update. Available from: www. effectivehealthcare.ahrq.gov/ehc/products/ 150/786/CER43-Off-LabelAntipsychotics- execsumm-20110928.pdf [Last accessed 5 September 2014]
16. Trifiro G, Gambassi G, Sen E, et al. Association of community acquired pneumonia with antipsychotic drug use in elderly patients. Ann Intern Med 2010;152: 418-25
17. Pratt N, Roughead E, Ramsay E, et al. Risk of hospitalization for hip fracture and pneumonia associated with antipsychotic prescribing in the elderly. Drug Saf 2011;34(7):567-75
18. Ballard C, Hanney M, Theodoulou M, et al. The dementia antipsychotic withdrawal trial (DART-AD): long term follow up of a randomised placebo-controlled trial. Lancet 2009;8: 151-7
19. Gerhard T, Huybrechts K, Olfson M, et al. Comparative mortality risks of antipsychotic medication in community-dwelling older adults. Br J Psych 2014;205:44-51
20. Tiihonen J, Lonnqvist J, Wahlbeck K, et al. 11-year followup of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009; 374(9690):620-7
21. Kales HC, Zivin K, Kim HM, Valenstein M. Trends in antipsychotic use in dementia. 1999Arch General Psych 2011; 68(2):190-7
22. Dorsey E, Rabanni A, Gallagher S, et al. Impact of FDA black box advisory on antipsychotic medication use. Arch Intern Med 2010;170(1):96-103
23. Ravindran AV, Al-Subaie A, Abraham G. Quetiapine: novel uses in the treatment of depressive and anxiety disorders. Expert Opin Investig Drugs 2010;19:1187-204
24. Glue P, Loan A, Gale C. New Prospects for the drug treatment of Generalized Anxiety Disorder - a systemic review. Curr Drug Ther 2010;5:86-94
25. Wiegand MH, Landry F, Bruckner T, et al. Quetiapine in primary insomnia: a pilot study. Psychopharmacology (Berl) 2008;196:337-8
26. Wine JN, Sanda C, Caballero J. Effects of quetiapine on sleep in nonpsychiatric and psychiatric conditions. Ann Pharmacother 2009;43(4):707-13
27. Cates M, Jackson C, Feldman J, et al. Metabolic consequences of using low dose quetiapine for insomnia in psychiatric patients. Community Ment Health J 2009;45:2551-4
28. Brecher M, Leong R, Stening G, et al. Quetiapine and long-term weight change: a comprehensive data review of patients with schizophrenia. J Clin Psychiatry 2007; 68(4):597-603
29. Ray W, Chung C, Murray K, et al. Atypical antipsychotics and the risk of sudden cardiac death. N Engl J Med 2009;360(3):225-35
30. Kuehn B. FDA panel issues mixed decision on quetiapine in depression and anxiety. JAMA 2009;301(20):2081-2
31. The Parkinson Study Group. Low-dose clozapine for the treatment of drug induced psychosis in Parkinson's Disease. N Engl J Med 1999;340(10):757-63